GlaxoSmithKline said further growth from the company’s shingles vaccine – which has boosted earnings – would be reined in by limited capacity until 2024, but a new bioreactor facility would then be ready to bring a step change in production.
GlaxoSmithKline beat second-quarter 2019 profit expectations with the help of strong demand for the company’s shingles vaccine, prompting the British drugmaker to forecast a smaller fall in profit for the full year than originally anticipated.
GlaxoSmithKline forecast 2019 sales of the company’s fast-growing shingles vaccine Shingrix to be “significantly” more than 1 billion pounds ($1.31 billion) as a drop in the British drugmaker’s free cash flow weighed on GSK’s shares.
GlaxoSmithKline is investing heavily in a Montana manufacturing facility that specializes in the manufacture of the company’s two-year-old shingles vaccine Shingrix, which is eying blockbuster status.
There were as many billion-dollar brands in 2017 as there have been in any other calendar year despite the cratering effects of massive patent cliffs in 2012 and 2015.
The committee responsible for U.S. vaccination schedules gave a preferential recommendation to GlaxoSmithKline’s newly approved shingles vaccine Shingrix over Merck’s established product Zostavax.
GlaxoSmithKline won U.S. approval for a new and improved shingles vaccine, the second of three key products the drugmaker expects approval for in 2017.
U.S. regulators approved GlaxoSmithKline’s three-in-one inhaler for chronic lung disease, a key new product as the group strives to keep its lead in respiratory medicine.
A U.S. Food and Drug Administration advisory panel voted 11-0 that the safety and efficacy of GlaxoSmithKline’s Shingrix shingles vaccine warrants approval for its use in adults aged 50 and over.
Shingrix induced a strong immune response in older adults previously been vaccinated against shingles with the currently available live-attenuated zoster vaccine.